Resultados de la búsqueda 71-80 of 283 for ������������������������������������:VB20��������������������� ������

  1. Medicina cardiovascular - Ensayos clínicos

    Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population.

  2. Medicina cardiovascular - Ensayos clínicos

    Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population.

  3. Ensayos clínicos - Medicina cardiovascular

    Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population.

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report ...

  5. Ensayos clínicos - Medicina cardiovascular

    Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population.

  6. Medicina cardiovascular - Ensayos clínicos

    Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population.

  7. Programa de tumores cerebrales - Ensayos clínicos

    It is not yet known whether giving memantine hydrochloride and WBRT with or without hippocampal avoidance works better in reducing neurocognitive decline in ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate the effects of ibrutinib and rituximab with or without venetoclax in treating patients with previously untreated ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate the effects of ibrutinib and rituximab with or without venetoclax in treating patients with previously untreated ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL.